HOME > TOP STORIES
TOP STORIES
-
BUSINESS Biogen to Challenge European Rejection of Aducanumab
December 20, 2021
-
BUSINESS Moderna to Develop All Global Pipeline Assets in Japan without Delay: Local Chief
December 17, 2021
-
BUSINESS Shionogi Pharma Eyes 10 Billion Yen Sales in CDMO Business in FY2022
December 17, 2021
-
REGULATORY Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
-
REGULATORY Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
-
REGULATORY Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
-
REGULATORY MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
-
BUSINESS Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
-
REGULATORY METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
-
REGULATORY Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
-
REGULATORY E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
-
ACADEMIA With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
-
REGULATORY Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
-
REGULATORY MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
-
BUSINESS EU Panel Backs Tocilizumab for Severe COVID-19: Chugai
December 8, 2021
-
BUSINESS Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
-
REGULATORY BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
-
BUSINESS Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
-
REGULATORY Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
-
REGULATORY MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
